Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neuro-Oncology
Published in: Journal of Neuro-Oncology 1/2023

Open Access 16-03-2023 | Glioblastoma | Research

Mortality trends in primary malignant brain and central nervous system tumors vary by histopathology, age, race, and sex

Authors: Marisa Thierheimer, Gino Cioffi, Kristin A. Waite, Carol Kruchko, Quinn T. Ostrom, Jill S. Barnholtz-Sloan

Published in: Journal of Neuro-Oncology | Issue 1/2023

Login to get access

Abstract

Purpose

Primary malignant brain and other central nervous system tumors are rare cancers that have shown rising mortality rates in recent years. To elucidate potential factors involved in this rising death rate, we examined mortality trends for primary malignant BT in the United States stratified by histopathology groupings, age, race, and sex.

Methods

Mortality rates for demographic factors within primary malignant BT were generated using the National Center for Health Statistics' National Vital Statistics Systems data from 2004 to 2018. Additionally, histopathology-specific incidence-based mortality rates were calculated using the National Cancer Institute’s Surveillance, Epidemiology, and End-Results (SEER) 18 data from 2004 to 2018. Joinpoint modeling was used to estimate mortality trends and annual percent changes with corresponding 95% confidence intervals.

Results

Overall, there was a very small increase in mortality from 2004 to 2018. Individuals > 65 years saw a small increase in mortality, while changes in individuals of other ages were non-significant. Asian/Pacific Islander or American Indian/Alaskan Native had the largest increase in mortality. Among histopathology groupings, there was a small mortality increase in adults ages > 65 years with glioblastoma, while the mortality rate of other malignant gliomas declined in the same age group. CNS lymphoma mortality rates in patients ages 15–39 and 40–64 years declined significantly while rising significantly in the > 65 age group. In pediatric patients, embryonal tumor mortality had a non-significant increase between 2004 and 2007 but declined significantly between 2007 and 2018.

Conclusion

Examining age, race, sex, and histopathology-specific mortality trends at the population level can provide important information for clinicians, researchers, and aid in public health planning.
Appendix
Available only for authorised users
Literature
1.
Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33CrossRefPubMed
2.
Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS (2022) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol 24(Supplement_5):v1–v95CrossRefPubMed
3.
Henley SJ, Ward EM, Scott S et al (2020) Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer 126(10):2225–2249CrossRefPubMed
4.
Surveillance Epidemiology and End Results (SEER) Program (2022) SEER*Stat database: incidence-based mortality— SEER 18 regs (Excl Louisiana) research data, Nov 2020 Sub (2000–2018) <Katrina/Rita population adjustment>—linked to county attributes—total U.S., 1969–2018 counties, National Cancer Institute, DCCPS, surveillance research program, surveillance systems branch, released May 2022, based on the November 2014 submission.
5.
Surveillance Epidemiology and End Results (SEER) Program (2022) SEER*Stat database: mortality—all COD, aggregated with state, total U.S. (2000–2018) <Katrina/Rita population adjustment>, National Cancer Institute, DCCPS, surveillance research program, surveillance systems branch, released May 2022. Underlying mortality data provided by NCHS (http:// www.​cdc.​gov/​nchs).
6.
Surveillance Epidemiology and End Results (SEER) Program (2022) SEER*Stat software version 8.4.0.1. National Cancer Institute, DCCPS, Surveillance Research Program. http://​www.​seer. cancer.gov/seerstat.
7.
Ostrom QT, Price M, Ryan K et al (2022) CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro Oncol 24(Supplement_3):iii1–iii38CrossRefPubMed
8.
World Health Organization. (‎2013)‎. International classification of diseases for oncology (‎ICD-O)‎, 3rd ed., 1st revision. World Health Organization.
9.
Joinpoint Regression Program, Version 4.9.1.0 - April 2022; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute.
10.
Surveillance Epidemiology and End Results (SEER) Program (2022) SEER*Stat database: incidence—SEER 18 regs (Excl Louisiana) research data, Nov 2020 Sub (2000–2018) <Katrina/Rita population adjustment>—linked to county attributes—total U.S., 1969–2018 counties, National Cancer Institute, DCCPS, surveillance research program, surveillance systems branch, released May 2022, based on the November 2014 submission .
11.
Fay MP (1999) Approximate confidence intervals for rate ratios from directly standardized rates with sparse data. Commun Stat Theory Methods 28(9):2141–2160CrossRef
12.
13.
Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 14(suppl 5):v1–v49CrossRefPubMedPubMedCentral
14.
15.
Ward E, DeSantis C, Robbins A, Kohler B, Jemal A (2014) Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64(2):83–103CrossRefPubMed
16.
17.
Legler JM, Ries LAG, Smith MA et al (1999) Brain and other central nervous system cancers: recent trends in incidence and mortality. JNCI J Nat Cancer Inst 91(16):1382–1390CrossRefPubMed
18.
Miller KD, Fidler-Benaoudia M, Keegan TH, Hipp HS, Jemal A, Siegel RL (2020) Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin 70(6):443–459CrossRefPubMed
19.
Miller KD, Ostrom QT, Kruchko C et al (2021) Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin 71(5):381–406CrossRefPubMed
20.
Gittleman HR, Ostrom QT, Rouse CD et al (2015) Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. Cancer 121(1):102–112CrossRefPubMed
21.
Ostrom QT, de Blank PM, Kruchko C et al (2015) Alex’s lemonade stand foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16(Suppl_10):x1–x36CrossRefPubMed
22.
23.
Zebrack BJ, Gurney JG, Oeffinger K et al (2004) Psychological outcomes in long-term survivors of childhood brain cancer: a report from the childhood cancer survivor study. J Clin Oncol 22(6):999–1006CrossRefPubMed
24.
Ris MD, Leisenring WM, Goodman P et al (2019) Neuropsychological and socioeconomic outcomes in adult survivors of pediatric low-grade glioma. Cancer 125(17):3050–3058CrossRefPubMed
25.
26.
Gittleman H, Kromer C, Ostrom QT et al (2017) Is mortality due to primary malignant brain and other central nervous system tumors decreasing? J Neurooncol 133(2):265–275CrossRefPubMed
27.
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMed
28.
29.
30.
Mason M, Laperriere N, Wick W et al (2016) Glioblastoma in the elderly: making sense of the evidence. Neurooncol Pract 3(2):77–86PubMed
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
Metadata
Title
Mortality trends in primary malignant brain and central nervous system tumors vary by histopathology, age, race, and sex
Authors
Marisa Thierheimer
Gino Cioffi
Kristin A. Waite
Carol Kruchko
Quinn T. Ostrom
Jill S. Barnholtz-Sloan
Publication date
16-03-2023
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 1/2023
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-023-04279-6

Other articles of this Issue 1/2023

Journal of Neuro-Oncology 1/2023 Go to the issue

Research

Social media insights for neurosurgical oncologists: a survey of the American Association of Neurological Surgeons and Congress of Neurological Surgeons Joint Section on Tumors

Research

Using the deformity index of vital structures to predict outcome of patients with large vestibular schwannomas after Gamma Knife radiosurgery

Research

Radiosurgery outcomes in infratentorial juvenile pilocytic astrocytomas

Research

T7 peptide-decorated exosome-based nanocarrier system for delivery of Galectin-9 siRNA to stimulate macrophage repolarization in glioblastoma

Case Study

Occurrence of non-central nervous system cancers during postoperative follow-up of patients who underwent surgery for a WHO grade II glioma: implications for therapeutic management

Review

A review on genetic alterations in CNS metastases related to breast cancer treatment. Is there a role for liquid biopsies in CSF?